ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00211185
Recruitment Status : Unknown
Verified March 2008 by Eisai Inc..
Recruitment status was:  Active, not recruiting
First Posted : September 21, 2005
Last Update Posted : August 28, 2009
Sponsor:
Information provided by:
Eisai Inc.

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : August 2008
  Study Completion Date : No date given

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 July 12, 2017
August 15, 2017
Publications of Results:
Francine M. Foss, Nelida Sjak-Shie, Andre Goy, Ranjana Advani, Eric Jacobsen, and Mark Acosta A Phase II Study of Denileukin Diftitox (Ontak®) with CHOP Chemotherapy in Patients with Newly-Diagnosed Aggressive T-Cell Lymphomas, the CONCEPT Trial: Interim Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2461.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):